Biphenyl compounds useful as muscarinic receptor antagonists

Abstract

The invention provides compounds of formula I: wherein a, b, c, m, s, t, W, Z, Ar, R 1 , R 2 , R 3 , R 6 , and R 7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

What is claimed is: 
     
       1. A compound of formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 a is 0 or an integer of from 1 to 5; 
 each R 1  is independently selected from —C 1-5 alkyl, —C 2-5 alkenyl, —C 2-5 alkynyl, —C 3-6 cycloalkyl, -cyano, -halo, —OR 1a , —C(O)OR 1b , —SR 1c , —S(O)R 1d , —S(O) 2 R 1e , —NR 1f R 1g , —NR 1h S(O) 2 R 1i , and —NR 1j C(O)R 1k ; where each of R 1a-1k  is independently —H, —C 1-5 alkyl or phenyl-C 1-5 alkyl; 
 b is 0 or an integer of from 1 to 4; 
 each R 2  is independently selected from —C 1-5 alkyl, —C 2-5 alkenyl, —C 2-5 alkynyl, —C 3-6 cycloalkyl, -cyano, -halo, —OR 2a , —C(O)OR 2b , —SR 2c , —S(O)R 2d , —S(O) 2 R 2e , —NR 2f R 2g , —NR 2h S(O) 2 R 2i , and —NR 2j C(O)R 2k ; where each of R 2a-2k  is independently —H, —C 1-5 alkyl or -phenyl-C 1-5 alkyl; 
 W is —O— or —NW a -, where W a  is —H or —C 1-5 alkyl; 
 c is 0 or an integer from 1 to 5; 
 each R 3  independently is —C 1-5 alkyl or two R 3  groups are joined to form C 1-3 alkylene, C 2-3 alkenylene or oxiran-2,3-diyl; 
 m is 0 or 1; 
 Z is selected from —C(O)N(R 4 )— and —N(R 4 )C(O)—, where R 4  is selected from —H, —C 1-5 alkyl, and —C 3-5 cycloalkyl; 
 s is 0, 1 or 2; 
 Ar is a C 3-5 heteroarylene group selected from pyridylene, thienylene, pyrrolylene, and furylene; wherein the C 3-5 heteroarylene group is substituted with (R 5 ) q  where q is 0 or an integer from 1 to 4 and each R 5  is independently selected from -halo, —OH, —C 1-5 alkyl, and —C 1-5 alkoxy; 
 t is 0, 1 or 2; 
 R 6  and R 7  are taken together to form: 
 
       
         
           
           
               
               
           
         
       
       optionally substituted with one to three —C 1-5 alkyl groups, or 
       
         
           
           
               
               
           
         
       
       where: d is 1 or 2; e is 0, 1 or 2; f is 0, 1, 2 or 3; R 8  is selected from —C 1-5 alkyl and ═O; R 9  is selected from —H, —C 1-5 alkyl, hydroxyphenyl, heteroaryl, and —X 9 R 9a ; where X 9  is selected from —C 1-5 alkylene, —C(O)—, —C 1-5 alkylene-C(O)—, —C(O)—C 1-5 alkylene, —S(O 2 )—, —C 1-5 alkylene-S(O 2 )—, and —S(O 2 )—C 1-5 alkylene; and R 9a  is selected from —H, —OH, —C 1-5 alkyl, —C 1-5 alkoxy, aryl, heteroaryl, heterocyclyl, and —NR 9b R 9c , where R 9b  and R 9c  are independently —H or —C 1-5 alkyl;
 wherein each alkyl and alkoxy group in R 1 , R 1a-1k , R 2 , R 2a-2k , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 9a-c  is optionally substituted with 1 to 5 fluoro substituents; 
 or a pharmaceutically acceptable salt or stereoisomer thereof. 
 
     
     
       2. The compound of  claim 1 , wherein a, b and c each represent 0. 
     
     
       3. The compound of  claim 1 , wherein W is —O—. 
     
     
       4. The compound of  claim 1 , wherein m is 0 and t is 1. 
     
     
       5. The compound of  claim 1 , wherein Z is selected from —NHC(O)—, —N(CH 3 )C(O)—, and —C(O)NH—. 
     
     
       6. The compound of  claim 1 , wherein Ar is selected from 2,5-pyridylene, 2,5-thienylene, 2,4-pyrrolylene, 2,5-pyrrolylene, and 2,5-furylene. 
     
     
       7. The compound of  claim 3 , wherein m is 0 and t is 1. 
     
     
       8. The compound of  claim 7 , wherein a, b, and c are 0; and Z is selected from —NHC(O)—, —N(CH 3 )C(O)—, and —C(O)NH—. 
     
     
       9. The compound of  claim 1 , wherein R 6  and R 7  are taken together to form: 
       
         
           
           
               
               
           
         
       
     
     
       10. The compound of  claim 1 , wherein R 6  and R 7  are taken together to form: 
       
         
           
           
               
               
           
         
       
       optionally substituted with two —C 1-5 alkyl groups. 
     
     
       11. The compound of  claim 1 , wherein R 6  and R 7  are taken together to form: 
       
         
           
           
               
               
           
         
       
       where: d is 1; e is 0; f is 1; R 8  is ═O and R 9  is —H. 
     
     
       12. The compound of  claim 1 , wherein R 6  and R 7  are taken together to form: 
       
         
           
           
               
               
           
         
       
       where: d is 1; e and f are 0; and R 9  is selected from —C 1-5 alkyl, hydroxyphenyl, heteroaryl, —C 1-5 alkylene-C 1-5 alkoxy, —C 1-5 alkyleneheteroaryl, —C(O)H, —C(O)—C 1-5 alkyl, —C(O)—C 1-5 alkoxy, —C(O)-heterocyclyl, —C(O)—NR 9b R 9c , —C 1-5 alkylene-C(O)-heterocyclyl, —C 1-5 alkylene-C(O)—NR 9b R 9c , and —S(O 2 )—C 1-5 alkyl; and wherein each alkyl and alkoxy group in R 9  and R 9b-c  is optionally substituted with 1 to 5 fluoro substituents. 
     
     
       13. The compound of  claim 1 , wherein R 6  and R 7  are taken together to form: 
       
         
           
           
               
               
           
         
       
       where: d is 2; e and f are 0; and R 9  is —C(O)—C 1-5 alkyl such as methyl; and wherein the alkyl group in R 9  is optionally substituted with 1 to 5 fluoro substituents. 
     
     
       14. The compound of  claim 1 , wherein R 6  and R 7  are taken together to form: 
       
         
           
           
               
               
           
         
       
       where: d and e are 1; f is 0; and R 9  is selected from —H and —C 1-5 alkylenearyl; and wherein the alkyl group in R 9  is optionally substituted with 1 to 5 fluoro substituents. 
     
     
       15. The compound of  claim 1 , selected from:
 biphenyl-2-ylcarbamic acid 1-{2-[methyl-(5-morpholin-4-ylmethylpyridine-2-carbonyl)amino]ethyl}piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-formylpiperazin-1-ylmethyl)pyridine-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{methyl-[5-(3-oxo-piperazin-1-ylmethyl)pyridine-2-carbonyl]amino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetyl-[1,4]diazepan-1-ylmethyl)pyridine-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetylpiperazin-1-ylmethyl)pyridine-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-methanesulfonylpiperazin-1-ylmethyl)pyridine-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 4-[6-({2-[4-(biphenyl-2-ylcarbamoyloxy)piperidin-1-yl]ethyl}methylcarbamoyl)pyridin-3-ylmethyl]piperazine-1-carboxylic acid methyl ester; 
 biphenyl-2-ylcarbamic acid 1-{2-[methyl-(5-morpholin-4-ylmethylthiophene-2-carbonyl)amino]ethyl}piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-formylpiperazin-1-ylmethyl)thiophene-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-yl-carbamic acid 1-(2-{methyl-[5-(3-oxopiperazin-1-ylmethyl)thiophene-2-carbonyl]amino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetyl-[1,4]diazepan-1-ylmethyl)thiophene-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 4-[5-({2-[4-(biphenyl-2-ylcarbamoyloxy)piperidin-1-yl]ethyl}methylcarbamoyl) thiophen-2-ylmethyl]piperazine-1-carboxylic acid methyl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(1,1-dioxo-1λ 6 -thiomorpholin-4-ylmethyl) thiophene-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetylpiperazin-1-ylmethyl)thiophene-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-methanesulfonylpiperazin-1-ylmethyl) thiophene-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetylpiperazin-1-ylmethyl)-1H-pyrrole-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-{2-[methyl(5-morpholin-4-ylmethylfuran-2-carbonyl)amino]ethyl}piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-formylpiperazin-1-ylmethyl)furan-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-yl-carbamic acid 1-(2-{methyl-[5-(3-oxopiperazin-1-ylmethyl)furan-2-carbonyl]amino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetyl[1,4]diazepan-1-ylmethyl)furan-2-carbonyl]ethylamino}ethyl)piperidin-4-yl ester; 
 4-[5-({2-[4-(biphenyl-2-ylcarbamoyloxy)piperidin-1-yl]ethyl}methylcarbamoyl)furan-2-ylmethyl]piperazine-1-carboxylic acid methyl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(1,1-dioxo-1λ 6 -thiomorpholin-4-ylmethyl)furan-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-acetylpiperazin-1-ylmethyl)furan-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; and 
 biphenyl-2-ylcarbamic acid 1-(2-{[5-(4-methanesulfonylpiperazin-1-ylmethyl)furan-2-carbonyl]methylamino}ethyl)piperidin-4-yl ester; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of  claim 1 . 
     
     
       17. The compound of  claim 1  prepared by the process comprising:
 (a) reacting a compound of formula II: 
 
       
         
           
           
               
               
           
         
       
       or a salt thereof, with a compound of formula III: 
       
         
           
           
               
               
           
         
       
       wherein L 1  represents a leaving group; or
 (b) coupling a compound of formula IVa: 
 
       
         
           
           
               
               
           
         
       
       or a reactive derivative thereof, with a compound of formula Va: 
       
         
           
           
               
               
           
         
       
       or coupling a compound of formula IVb: 
       
         
           
           
               
               
           
         
       
       with a compound of formula Vb: 
       
         
           
           
               
               
           
         
       
       or a reactive derivative thereof; or
 (c) reacting a compound of formula VI: 
 
       
         
           
           
               
               
           
         
       
       wherein L 2  represents a leaving group, with a compound of formula VII: 
       
         
           
           
               
               
           
         
       
       or
 (d) reacting a compound of formula II with a compound of formula VIII: 
 
       
         
           
           
               
               
           
         
       
       in the presence of a reducing agent; or
 (e) reacting a compound of formula IX: 
 
       
         
           
           
               
               
           
         
       
       with a compound of formula VII in the presence of a reducing agent; and then
 (f) removing any protecting groups that may be present to provide a compound of formula I. 
 
     
     
       18. The compound of  claim 17 , prepared by the process which further comprises forming a pharmaceutically acceptable salt of the compound of formula I.